Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
World Journal of Surgical Oncology
Published in: World Journal of Surgical Oncology 1/2018

Open Access 01-12-2018 | Research

MiR-218 produces anti-tumor effects on cervical cancer cells in vitro

Authors: Li Zhu, Huaidong Tu, Yanmei Liang, Dihong Tang

Published in: World Journal of Surgical Oncology | Issue 1/2018

Login to get access

Abstract

Background

As indoleamine-2,3-dioxygenase 1 (IDO1) is critical in tumor immune escape, we determined to study the regulatory mechanism of miR-218 on IDO1 in cervical cancer.

Methods

Real-time PCR (RT-qPCR) was carried out to measure the expression of miR-218. RT-qPCR and Western blot were performed to detect the expression of IDO1 in cervical cancer. Dual-luciferase reporter assay was used to determine the binding of miR-218 on the IDO1 3′UTR. Cell viability, apoptosis, and related factors were determined using cell counting kit-8 (CCK-8), Annexin-V/PI (propidium) assay, enzyme-linked immunosorbnent assay (ELISA), RT-qPCR, and Western blot assays after miR-218 mimics has been transfected to HeLa cervical cancer cells.

Results

MiR-218 was downregulated in cervical cancer. The expression of miR-218 was negatively correlated with IDO1 in cervical cancer tissues and cells. IDO1 is a direct target of miR-218. MiR-218 overexpression was found to inhibit cell viability and promoted apoptosis via activating the expression of Cleaved-Caspase-3 and to inhibit the expression of Survivin, immune factors (TGF-β, VEGF, IL-6, PGE2, COX-2), and JAK2/STAT3 pathway.

Conclusion

MiR-218 inhibits immune escape of cervical cancer cells by direct downregulating IDO1.
Literature
1.
Flanagan MB. Primary high-risk human papillomavirus testing for cervical cancer screening in the United States: is it time? Arch Pathol Lab Med. 2018;142:688–92.CrossRef
2.
Feng C, Dong J, Chang W, Cui M, Xu T. The progress of methylation regulation in gene expression of cervical cancer. Int J Genomics. 2018;2018:8260652.CrossRef
3.
Tzafetas M, Mitra A, Kalliala I, Lever S, Fotopoulou C, Farthing A, Smith JR, Martin-Hirsch P, Paraskevaidis E, Kyrgiou M. Fertility-sparing surgery for presumed early-stage invasive cervical cancer: a survey of practice in the United Kingdom. Anticancer Res. 2018;38:3641–6.CrossRef
4.
He X, Li JP, Liu XH, Zhang JP, Zeng QY, Chen H, Chen SL. Prognostic value of C-reactive protein/albumin ratio in predicting overall survival of Chinese cervical cancer patients overall survival: comparison among various inflammation based factors. J Cancer. 2018;9:1877–84.CrossRef
5.
Lee KB, Shim SH, Lee JM. Comparison between adjuvant chemotherapy and adjuvant radiotherapy/chemoradiotherapy after radical surgery in patients with cervical cancer: a meta-analysis. J Gynecol Oncol. 2018;29:e62.CrossRef
6.
Vazquez-Sanchez AY, Hinojosa LM, Parraguirre-Martinez S, Gonzalez A, Morales F, Montalvo G, Vera E, Hernandez-Gallegos E, Camacho J. Expression of KATP channels in human cervical cancer: potential tools for diagnosis and therapy. Oncol Lett. 2018;15:6302–8.PubMedPubMedCentral
7.
Zhu M, Feng M, He F, Han B, Ma K, Zeng X, Liu Z, Liu X, Li J, Cao H, et al. Pretreatment neutrophil-lymphocyte and platelet-lymphocyte ratio predict clinical outcome and prognosis for cervical cancer. Clin Chim Acta. 2018;483:296–302.CrossRef
8.
Fahey LM, Raff AB, Da Silva DM, Kast WM. A major role for the minor capsid protein of human papillomavirus type 16 in immune escape. J Immunol. 2009;183:6151–6.CrossRef
9.
Song H, Park H, Park G, Kim YS, Lee HK, Jin DH, Kang HS, Cho DH, Hur D. Corticotropin-releasing factor induces immune escape of cervical cancer cells by downregulation of NKG2D. Oncol Rep. 2014;32:425–30.CrossRef
10.
Zhang H, Zhang S. The expression of Foxp3 and TLR4 in cervical cancer: association with immune escape and clinical pathology. Arch Gynecol Obstet. 2017;295:705–12.CrossRef
11.
Wang N, Wang Z, Xu Z, Chen X, Zhu G. A cisplatin-loaded immunochemotherapeutic nanohybrid bearing immune checkpoint inhibitors for enhanced cervical cancer therapy. Angew Chem Int Ed Engl. 2018;57:3426–30.CrossRef
12.
Niebler M, Qian X, Hofler D, Kogosov V, Kaewprag J, Kaufmann AM, Ly R, Bohmer G, Zawatzky R, Rosl F, Rincon-Orozco B. Post-translational control of IL-1beta via the human papillomavirus type 16 E6 oncoprotein: a novel mechanism of innate immune escape mediated by the E3-ubiquitin ligase E6-AP and p53. PLoS Pathog. 2013;9:e1003536.CrossRef
13.
Conesa-Zamora P. Immune responses against virus and tumor in cervical carcinogenesis: treatment strategies for avoiding the HPV-induced immune escape. Gynecol Oncol. 2013;131:480–8.CrossRef
14.
Fausch SC, Da Silva DM, Rudolf MP, Kast WM. Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses. J Immunol. 2002;169:3242–9.CrossRef
15.
Medema JP, de Jong J, Peltenburg LT, Verdegaal EM, Gorter A, Bres SA, Franken KL, Hahne M, Albar JP, Melief CJ, Offringa R. Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proc Natl Acad Sci U S A. 2001;98:11515–20.CrossRef
16.
Williams DK, Markwalder JA, Balog AJ, Chen B, Chen L, Donnell J, Haque L, Hart AC, Mandal SK, Nation A, et al. Development of a series of novel o-phenylenediamine-based indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors. Bioorg Med Chem Lett. 2018;28:732–6.CrossRef
17.
Cheong JE, Sun L. Targeting the IDO1/TDO2-KYN-AhR pathway for cancer immunotherapy - challenges and opportunities. Trends Pharmacol Sci. 2018;39:307–25.CrossRef
18.
Zou Y, Wang Y, Wang F, Luo M, Li Y, Liu W, Huang Z, Zhang Y, Guo W, Xu Q, Lai Y. Discovery of potent IDO1 inhibitors derived from tryptophan using scaffold-hopping and structure-based design approaches. Eur J Med Chem. 2017;138:199–211.CrossRef
19.
Davar D, Bahary N. Modulating tumor immunology by inhibiting indoleamine 2,3-dioxygenase (IDO): recent developments and first clinical experiences. Target Oncol. 2018;13:125–40.CrossRef
20.
Folgiero V, Cifaldi L, Li Pira G, Goffredo BM, Vinti L, Locatelli F. TIM-3/Gal-9 interaction induces IFNgamma-dependent IDO1 expression in acute myeloid leukemia blast cells. J Hematol Oncol. 2015;8:36.CrossRef
21.
Pan K, Wang H, Chen MS, Zhang HK, Weng DS, Zhou J, Huang W, Li JJ, Song HF, Xia JC. Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2008;134:1247–53.CrossRef
22.
?>Folgiero V, Miele E, Carai A, Ferretti E, Alfano V, Po A, Bertaina V, Goffredo BM, Benedetti MC, Camassei FD, et al. IDO1 involvement in mTOR pathway: a molecular mechanism of resistance to mTOR targeting in medulloblastoma. Oncotarget. 2016;7:52900–11.CrossRef
23.
Moretti S, Menicali E, Voce P, Morelli S, Cantarelli S, Sponziello M, Colella R, Fallarino F, Orabona C, Alunno A, et al. Indoleamine 2,3-dioxygenase 1 (IDO1) is up-regulated in thyroid carcinoma and drives the development of an immunosuppressant tumor microenvironment. J Clin Endocrinol Metab. 2014;99:E832–40.CrossRef
24.
Boscke R, Vladar EK, Konnecke M, Husing B, Linke R, Pries R, Reiling N, Axelrod JD, Nayak JV, Wollenberg B. Wnt signaling in chronic rhinosinusitis with nasal polyps. Am J Respir Cell Mol Biol. 2017;56(5):575–84.CrossRef
25.
Hascitha J, Priya R, Jayavelu S, Dhandapani H, Selvaluxmy G, Sunder Singh S, Rajkumar T. Analysis of kynurenine/tryptophan ratio and expression of IDO1 and 2 mRNA in tumour tissue of cervical cancer patients. Clin Biochem. 2016;49:919–24.CrossRef
26.
Mittal D, Kassianos AJ, Tran LS, Bergot AS, Gosmann C, Hofmann J, Blumenthal A, Leggatt GR, Frazer IH. Indoleamine 2,3-dioxygenase activity contributes to local immune suppression in the skin expressing human papillomavirus oncoprotein e7. J Invest Dermatol. 2013;133:2686–94.CrossRef
27.
Punt S, Houwing-Duistermaat JJ, Schulkens IA, Thijssen VL, Osse EM, de Kroon CD, Griffioen AW, Fleuren GJ, Gorter A, Jordanova ES. Correlations between immune response and vascularization qRT-PCR gene expression clusters in squamous cervical cancer. Mol Cancer. 2015;14:71.CrossRef
28.
Gao Y, Sun L, Wu Z, Xuan C, Zhang J, You Y, Chen X. miR218 inhibits the proliferation of human glioma cells through downregulation of Yin Yang 1. Mol Med Rep. 2018;17:1926–32.PubMed
29.
Cong R, Tao K, Fu P, Lou L, Zhu Y, Chen S, Cai X, Mao L. MicroRNA218 promotes prostaglandin E2 to inhibit osteogenic differentiation in synovial mesenchymal stem cells by targeting 15hydroxyprostaglandin dehydrogenase [NAD(+)]. Mol Med Rep. 2017;16:9347–54.CrossRef
30.
Guan B, Wu K, Zeng J, Xu S, Mu L, Gao Y, Wang K, Ma Z, Tian J, Shi Q, et al. Tumor-suppressive microRNA-218 inhibits tumor angiogenesis via targeting the mTOR component RICTOR in prostate cancer. Oncotarget. 2017;8:8162–72.PubMed
31.
Wang J, Ying Y, Bo S, Li G, Yuan F. Differentially expressed microRNA-218 modulates the viability of renal cell carcinoma by regulating BCL9. Mol Med Rep. 2016;14:1829–34.CrossRef
32.
Li F, Zhang R, Li S, Liu J. IDO1: an important immunotherapy target in cancer treatment. Int Immunopharmacol. 2017;47:70–7.CrossRef
33.
Li S, Gong X, Chen Q, Zheng F, Ji G, Liu Y. Threshold level of Riemerella anatipestifer crossing blood-brain barrier and expression profiles of immune-related proteins in blood and brain tissue from infected ducks. Vet Immunol Immunopathol. 2018;200:26–31.CrossRef
34.
Heldin, C.H. Development and possible clinical use of antagonists for PDGF and TGF-beta.Ups J Med Sci. 2004;109(3):165.
35.
Yang J, Yan J, Liu B. Targeting VEGF/VEGFR to modulate antitumor immunity. Front Immunol. 2018;9:978.CrossRef
36.
Shibao S, Ueda R, Saito K, Kikuchi R, Nagashima H, Kojima A, Kagami H, Pareira ES, Sasaki H, Noji S, et al. A pilot study of peptide vaccines for VEGF receptor 1 and 2 in patients with recurrent/progressive high grade glioma. Oncotarget. 2018;9:21569–79.CrossRef
37.
Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014;6:a016295.CrossRef
38.
Yang HM, Song WJ, Li Q, Kim SY, Kim HJ, Ryu MO, Ahn JO, Youn HY. Canine mesenchymal stem cells treated with TNF-alpha and IFN-gamma enhance anti-inflammatory effects through the COX-2/PGE2 pathway. Res Vet Sci. 2018;119:19–26.CrossRef
39.
Trabanelli S, Lecciso M, Salvestrini V, Cavo M, Ocadlikova D, Lemoli RM, Curti A. PGE2-induced IDO1 inhibits the capacity of fully mature DCs to elicit an in vitro antileukemic immune response. J Immunol Res. 2015;2015:253191.PubMedPubMedCentral
40.
Carvalho MI, Bianchini R, Fazekas-Singer J, Herrmann I, Flickinger I, Thalhammer JG, Pires I, Jensen-Jarolim E, Queiroga FL. Bidirectional regulation of COX-2 expression between cancer cells and macrophages. Anticancer Res. 2018;38:2811–7.PubMed
41.
Kim HG, Kim YR, Park JH, Khanal T, Choi JH, Do MT, Jin SW, Han EH, Chung YH, Jeong HG. Endosulfan induces COX-2 expression via NADPH oxidase and the ROS, MAPK, and Akt pathways. Arch Toxicol. 2015;89:2039–50.CrossRef
42.
Cesario A, Rocca B, Rutella S. The interplay between indoleamine 2,3-dioxygenase 1 (IDO1) and cyclooxygenase (COX)-2 in chronic inflammation and cancer. Curr Med Chem. 2011;18:2263–71.CrossRef
43.
Wu Y, et al. Study on the mechanism of JAK2/STAT3 signaling pathway-mediated inflammatory reaction after cerebral ischemia. Molecular Medicine Reports, 2018; 17(4).
44.
Wang T, Chen D, Wang P, Xu Z, Li Y. miR-375 prevents nasal mucosa cells from apoptosis and ameliorates allergic rhinitis via inhibiting JAK2/STAT3 pathway. Biomed Pharmacother. 2018;103:621–7.CrossRef
45.
Wang Y, Wong CW, Yan M, Li L, Liu T, Mei-Yu Or P, Kwok-Wing Tsui S, Miu-Yee Waye M, Man-Lok Chan A. Differential regulation of the pro-inflammatory biomarker, YKL-40/CHI3L1, by PTEN/phosphoinositide 3-kinase and JAK2/STAT3 pathways in glioblastoma. Cancer Lett. 2018;429:54–65.CrossRef
46.
Zhao Z, Han Y, Zhang Z, Li W, Ji X, Liu X, Jin J, Xu S, Cui H, Cheng Z, et al. Total glucosides of paeony improves the immunomodulatory capacity of MSCs partially via the miR-124/STAT3 pathway in oral lichen planus. Biomed Pharmacother. 2018;105:151–8.CrossRef
Metadata
Title
MiR-218 produces anti-tumor effects on cervical cancer cells in vitro
Authors
Li Zhu
Huaidong Tu
Yanmei Liang
Dihong Tang
Publication date
01-12-2018
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2018
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/s12957-018-1506-3

Other articles of this Issue 1/2018

World Journal of Surgical Oncology 1/2018 Go to the issue

Case Report

A dural metastatic small cell carcinoma of the gallbladder as the first manifestation: a case report

Research

Identification of hub genes with diagnostic values in pancreatic cancer by bioinformatics analyses and supervised learning methods

Research

The impact of adjuvant therapies on patient survival and the recurrence patterns for resected stage IIa–IVa lower thoracic oesophageal squamous cell carcinoma

Technical innovations

Laparoscopic intersphincteric resection with intraoperative radiotherapy using low-energy X-rays for locally advanced ultra-low rectal cancer

Research

The clinicopathological significance of Ki67 in papillary thyroid carcinoma: a suitable indicator?

Research

Identification of key gene modules for human osteosarcoma by co-expression analysis